RepliCel Price To Sales Ratio vs Capex To Depreciation Analysis
RP Stock | CAD 0.01 0.01 50.00% |
RepliCel Life financial indicator trend analysis is much more than just breaking down RepliCel Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RepliCel Life Sciences is a good investment. Please check the relationship between RepliCel Life Price To Sales Ratio and its Capex To Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Price To Sales Ratio vs Capex To Depreciation
Price To Sales Ratio vs Capex To Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RepliCel Life Sciences Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between RepliCel Life's Price To Sales Ratio and Capex To Depreciation is -0.33. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of RepliCel Life Sciences, assuming nothing else is changed. The correlation between historical values of RepliCel Life's Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of RepliCel Life Sciences are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., RepliCel Life's Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.
Correlation Coefficient | -0.33 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing RepliCel Life Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on RepliCel Life sales, a figure that is much harder to manipulate than other RepliCel Life Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most indicators from RepliCel Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, RepliCel Life's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.46 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.54) in 2024.
RepliCel Life fundamental ratios Correlations
Click cells to compare fundamentals
RepliCel Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
RepliCel Life fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Total Current Liabilities | 1.6M | 2.2M | 1.7M | 2.1M | 1.8M | 1.9M | |
Total Stockholder Equity | (4.4M) | (5.1M) | (6.8M) | (5.9M) | (4.5M) | (4.3M) | |
Property Plant And Equipment Net | 6.0K | 4.4K | 3.3K | 2.4K | 967.0 | 918.65 | |
Net Debt | 425.4K | 41.7K | (186.9K) | (372.1K) | 754.0K | 791.7K | |
Retained Earnings | (36.6M) | (38.2M) | (42.2M) | (43.0M) | (43.3M) | (41.1M) | |
Accounts Payable | 640.3K | 1.3M | 602.0K | 817.9K | 416.0K | 472.3K | |
Cash | 23.9K | 34.4K | 221.2K | 413.0K | 59.2K | 56.2K | |
Non Current Assets Total | 272.2K | 235.3K | 198.8K | 162.5K | 125.7K | 119.4K | |
Cash And Short Term Investments | 52.7K | 51.6K | 238.4K | 430.3K | 76.4K | 72.6K | |
Net Receivables | 51.9K | 63.6K | 61.2K | 82.2K | 38.0K | 39.0K | |
Common Stock Shares Outstanding | 24.1M | 27.0M | 32.5M | 37.8M | 59.2M | 62.2M | |
Liabilities And Stockholders Equity | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Other Stockholder Equity | 4.6M | 4.6M | 5.1M | 5.4M | 5.6M | 5.6M | |
Total Liab | 4.9M | 5.5M | 7.4M | 6.7M | 4.8M | 5.1M | |
Total Current Assets | 233.2K | 185.7K | 393.0K | 635.7K | 162.1K | 154.0K | |
Short Term Debt | 449.3K | 47.3K | 611.4K | 689.3K | 813.2K | 853.8K | |
Common Stock | 27.5M | 28.5M | 30.3M | 31.7M | 33.1M | 20.0M | |
Other Current Liab | 107.3K | 517.8K | 106.6K | 211.8K | 239.5K | 432.0K | |
Other Assets | 266.2K | 230.8K | 195.5K | 1.0 | 1.15 | 1.09 | |
Non Current Liabilities Total | 3.4M | 3.2M | 5.8M | 4.6M | 3.0M | 2.1M | |
Other Current Assets | 128.7K | 70.5K | 93.4K | 123.2K | 47.7K | 89.2K | |
Net Tangible Assets | (1.9M) | (4.4M) | (5.1M) | (6.8M) | (6.2M) | (5.9M) | |
Property Plant Equipment | 8.2K | 6.0K | 4.4K | 3.3K | 2.9K | 2.8K | |
Net Invested Capital | (2.9M) | (5.0M) | (6.8M) | (5.9M) | (5.3M) | (5.6M) | |
Net Working Capital | (1.2M) | (2.1M) | (1.3M) | (1.4M) | (1.3M) | (1.4M) | |
Capital Stock | 29.0M | 28.5M | 30.3M | 31.7M | 36.4M | 32.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.